Improving HIV prevention and care for adolescents and young adults in Uganda
Official title: Implementation Science to Understand and Design Stakeholder Informed Innovative Interventions to Improve Adolescent and Youth HIV Prevention and Care Continuums in Rural and Urban Uganda
Funded at Mu-Jhu Care · NIH-11395132 · Data updated 2026-11-12
This project will offer long-acting injectable HIV prevention and youth-centered care approaches to help adolescents and young adults in Uganda start and stay on effective prevention and treatment.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mu-Jhu Care NIH-funded |
| Lab location | 1 site (Kampala, Uganda) |
| Project start | September 8, 2023 |
| Project end | August 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $224,769 |
| NIH project number | 3UG1HD113241-03S3 |
| Project ID | NIH-11395132 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are adolescents and young adults (approximately 15–24 years old) in the study communities in Uganda who are either high-risk HIV-negative individuals eligible for PrEP or HIV-positive youth needing support to achieve viral suppression.
✕Less likely to help
People outside the 15–24 age range, those not living in participating Ugandan communities, or individuals with medical contraindications to cabotegravir or who refuse injections are unlikely to benefit directly from this project.
What this research studies
You and other young people (ages 15–24) will be screened using new methods to find who is at high risk for HIV. If you are HIV-negative and at risk, the project may offer long-acting injectable PrEP (cabotegravir) through community delivery to avoid daily pills. If you are living with HIV, you would be offered the SEARCH-Youth support package with life-stage tailored help to start and stay on treatment and reach viral suppression. The program is delivered in both rural and urban communities in Uganda and uses real-world delivery models while collecting health outcomes.
Why it matters
Potential benefit: If successful, this work could expand access to effective long-acting PrEP and improve viral suppression among adolescents and young adults, lowering new infections and improving health.
How similar studies have gone: Clinical trials have shown cabotegravir injections prevent HIV effectively, but delivering long-acting PrEP and youth-tailored care in routine community settings is newer and still being refined.
Where this research is happening
-
Mu-Jhu Care
Kampala, Uganda Active
Researchers
- Principal investigator: Musoke, Philippa — Mu-Jhu Care
- Study coordinator: Musoke, Philippa
Related research
Other NIH-funded projects on the same topics.
-
Making HIV prevention and care easier for Ugandan youth
A Ugandan study is testing ways to help adolescents and young adults (15–24) prevent HIV and stay healthy, using long-acting PrEP and youth-friendly services.
-
Innovative HIV Prevention and Care Interventions for Adolescents and Young Adults in Uganda
A Ugandan research team is testing practical, youth-focused strategies to help 15-24 year-olds using HIV prevention or treatment services stay healthy and engaged in care.
-
Improving HIV Prevention and Care for Ugandan Adolescents and Young Adults
A Uganda-based research effort aims to boost HIV prevention and care outcomes for 15-24 year-olds by testing practical, community-based strategies to increase PrEP use and viral suppression.
-
Adolescent and Youth HIV Prevention and Care Improvements in Uganda
A UG1 grant is testing ways to help Ugandan teens and young adults (ages 15-24) prevent HIV and stay healthy if they have HIV, using new long-acting PrEP and community care approaches.
-
Malkia Klabu: safer, youth-friendly pharmacies to boost HIV prevention for AGYW in Tanzania
A Tanzania-based project tests a youth-friendly pharmacy model to improve access to HIV prevention and sexual health services for adolescent girls and young women.
-
Innovative HIV Prevention and Care Interventions for Adolescents and Young Adults in Uganda
A Ugandan study tests new ways to help teens and young adults (ages 15–24) prevent HIV and stay healthy if they are living with HIV, using community-based options and long-acting PrEP.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.